RCKT

Rocket Pharmaceuticals Inc

RCKT, USA

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases in the United States. It develops vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage. It also develops vivo lentiviral (LV) programs, which include programs for Leukocyte Adhesion Deficiency-I (LAD-I), a genetic disorder that causes the immune system to malfunction (RP-L201); Fanconi Anemia (FA), a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells (RP-L102); and Pyruvate Kinase Deficiency (PKD), a red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia (RP-L301). It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; REGENXBIO, Inc.; and Temple University. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

https://www.rocketpharma.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
RCKT
stock
RCKT

We're Keeping An Eye On Rocket Pharmaceuticals' (NASDAQ:RCKT) Cash Burn Rate simplywall.st

Read more →
RCKT
stock
RCKT

Breakout Move: Will Aeva Technologies Inc stock remain a Wall Street favorite moha.gov.vn

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$7.9546

Analyst Picks

Strong Buy

12

Buy

5

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

1.23

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-16.05 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-13.68 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.17

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 80.80% of the total shares of Rocket Pharmaceuticals Inc

1.

RTW INVESTMENTS, LLC

(16.3922%)

since

2025/06/30

2.

Maverick Capital Ltd

(7.7512%)

since

2025/06/30

3.

BlackRock Inc

(6.8845%)

since

2025/06/30

4.

Vanguard Group Inc

(5.674%)

since

2025/06/30

5.

Suvretta Capital Management, LLC

(3.8398%)

since

2025/06/30

6.

MPM Oncology Impact Management LP

(3.6172%)

since

2025/06/30

7.

Morgan Stanley - Brokerage Accounts

(2.9369%)

since

2025/06/30

8.

Vanguard Total Stock Mkt Idx Inv

(2.5101%)

since

2025/07/31

9.

RTW Biotech Opportunities Ord

(2.2249%)

since

2024/12/31

10.

Millennium Management LLC

(2.1768%)

since

2025/06/30

11.

Geode Capital Management, LLC

(1.8821%)

since

2025/06/30

12.

iShares Russell 2000 ETF

(1.8684%)

since

2025/08/31

13.

Newtyn Management LLC

(1.8535%)

since

2025/06/30

14.

State Street Corp

(1.8013%)

since

2025/06/30

15.

Two Sigma Investments LLC

(1.599%)

since

2025/06/30

16.

Prosight Management, LP

(1.4648%)

since

2025/06/30

17.

Goldman Sachs Group Inc

(1.4601%)

since

2025/06/30

18.

Qube Research & Technologies

(1.4349%)

since

2025/06/30

19.

Two Sigma Advisers, LLC

(1.3811%)

since

2025/06/30

20.

JPMorgan Chase & Co

(1.1193%)

since

2025/06/30

21.

The Toronto-Dominion Bank

(1.0194%)

since

2025/06/30

22.

T. Rowe Price Associates, Inc.

(1.0193%)

since

2025/06/30

23.

D. E. Shaw & Co LP

(0.9201%)

since

2025/06/30

24.

Vanguard Institutional Extnd Mkt Idx Tr

(0.858%)

since

2025/07/31

25.

Fidelity Small Cap Index

(0.7842%)

since

2025/06/30

26.

Vanguard Explorer Inv

(0.6474%)

since

2025/06/30

27.

T. Rowe Price Health Sciences

(0.6308%)

since

2025/07/31

28.

HBM Healthcare Investments AG Ord

(0.6268%)

since

2025/06/30

29.

iShares Russell 2000 Value ETF

(0.5714%)

since

2025/08/31

30.

iShares Biotechnology ETF

(0.5461%)

since

2025/08/31

31.

Fidelity Extended Market Index

(0.4331%)

since

2025/07/31

32.

Nordea 2 - BetaPlus Enh GlSCap Eq BI USD

(0.3838%)

since

2025/07/31

33.

Schwab US Small-Cap ETF™

(0.3731%)

since

2025/08/30

34.

Vanguard Russell 2000 ETF

(0.3727%)

since

2025/07/31

35.

JPM Thematics Genetic Thrps C2 dist USD

(0.3703%)

since

2025/07/31

36.

Federated Hermes MDT Small Cap Core IS

(0.3088%)

since

2025/06/30

37.

Federated Hermes MDT SCC Institutional

(0.3088%)

since

2025/06/30

38.

State St Russell Sm Cap® Indx SL Cl I

(0.2612%)

since

2025/08/31

39.

Federated Hermes MDT SCG Institutional

(0.246%)

since

2025/06/30

40.

Federated Hermes MDT Small Cap Growth IS

(0.246%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.4247

Latest Release

Date

2025-09-30

EPS Actual

-0.45

EPS Estimate

-0.49

EPS Difference

0.04

Surprise Percent

8.1633%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(5)
Defensive
Moderately Defensive(5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.3)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(3)
Value
Undervalued(6.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.